PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for women with aggressive ovarian cancer
Disease control CompletedThis study tested whether adding a new drug called afuresertib to standard chemotherapy (paclitaxel) works better for women with ovarian cancer that has stopped responding to platinum-based drugs. About 150 participants were randomly assigned to receive either the combination or …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo tested for Tough-to-Treat ovarian cancer
Disease control CompletedThis study tested a new drug called ZN-c3, both by itself and combined with an existing drug (niraparib), for women with advanced ovarian cancer that had stopped responding to platinum chemotherapy. The main goals were to find safe doses and see if the treatments could shrink tum…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for Tough-to-Treat ovarian cancer
Disease control CompletedThis study tested a new drug called SL-172154, given alongside one of two standard chemotherapy drugs, in people with ovarian cancer that had stopped responding to platinum-based treatments. The main goals were to find a safe dose and see if the combinations showed early signs of…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC